Get the Stockscreener App
4.06
3.84%
0.15
Ardelyx Inc stock is traded at $4.06, with a volume of 3.97M.
It is up +3.84% in the last 24 hours and down -21.32% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$3.91
Open:
$3.93
24h Volume:
3.97M
Relative Volume:
0.99
Market Cap:
$1.05B
Revenue:
$427.68M
Net Income/Loss:
$-58.06M
P/E Ratio:
-17.04
EPS:
-0.2382
Net Cash Flow:
$-37.50M
1W Performance:
+1.50%
1M Performance:
-21.32%
6M Performance:
-40.90%
1Y Performance:
-30.48%
1-Day Range:
$3.86
$4.07
1-Week Range:
$3.86
$4.12
52-Week Range:
$3.86
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
4.06 | 1.03B | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Rubric Capital discloses 6.56% Ardelyx (ARDX) stake totaling 16.2M shares - Stock Titan
ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx - TradingView
Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) - Morningstar
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript - AOL.com
Ardelyx (ARDX) Is Down 19.1% After ESOP Shelf Filing And Higher 2026 Product Revenue Guidance - simplywall.st
Ardelyx (NASDAQ:ARDX) Hits New 12-Month LowShould You Sell? - MarketBeat
Ardelyx Q2 revenue up 31% but guidance cut due to payer issues, hold rating maintained - pluang.com
Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story (NASDAQ:ARDX) - Seeking Alpha
Ardelyx, Inc. (ARDX) stock price, news, quote and history - Yahoo Finance Singapore
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Is Ardelyx (ARDX) Undervalued Following Q2 Results And Updated Product Guidance? - simplywall.st
Ardelyx (ARDX): Millennium entities and Israel Englander report 5.7% stake in 13G/A - Stock Titan
Ardelyx, Inc. (ARDX) Stock Price, News, Quote & History - Yahoo Finance
HC Wainwright Estimates Ardelyx's Q3 Earnings (NASDAQ:ARDX) - MarketBeat
Ardelyx, Inc. (ARDX) interactive stock chart - sg.finance.yahoo.com
Ardelyx (ARDX) Is Down 19.7% After Raising IBSRELA Revenue Guidance And Narrowing Losses - Yahoo Finance
3 High Growth Stocks With Healthy Balance Sheets Retail Investors May Be Missing - simplywall.st
ARDX Maintained by Citigroup -- Price Target Lowered to $11.00 - GuruFocus
Citigroup Lowers Ardelyx (NASDAQ:ARDX) Price Target to $11.00 - MarketBeat
3 Financially Strong Penny Stocks Worth A Closer Look - simplywall.st
FY2027 EPS Estimates for Ardelyx Lowered by HC Wainwright - MarketBeat
3 Financially Fit Penny Stocks Retail Investors May Be Missing - simplywall.st
Ardelyx Stock Leads These Financially Fit Penny Stocks Worth A Closer Look - simplywall.st
Ardelyx Lawsuit 2026: Payouts, Eligibility, Updates - LawFold.com
Ardelyx (ARDX) Stock Slides As Payer Friction Clouds Growth Path - simplywall.st
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
Ardelyx Shares Fall After IBS Drug Sales Hit Snags - moomoo.com
ARDX Looks 61.5% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
ARDX Maintained by TD Cowen -- Price Target Lowered to $10.00 - GuruFocus
Ardelyx, Inc. Stock 12‑Month Price Target Cut to $13, Implies 167% Upside - TradingView
Ardelyx Inc earnings missed by $0.04, revenue fell short of estimates - Investing.com Nigeria
Why is Ardelyx stock plunging today? By Investing.com - Investing.com South Africa
Ardelyx stock hits 52-week low at 4.08 USD By Investing.com - Investing.com South Africa
ARDX Maintains by BTIG -- Price Target Lowered to $14.00 - GuruFocus
Why is Ardelyx stock plunging today? - Investing.com Nigeria
Ardelyx options trading surges as stock falls 18% By Investing.com - Investing.com Australia
ARDX Looks 59.7% Undervalued on GF Value™ Despite Revenue Outloo - GuruFocus
Ardelyx (ARDX) Posts Record Revenue, Is The Stock Still 70% Undervalued? - Yahoo Finance
Ardelyx options trading surges as stock falls 18% - Investing.com
Ardelyx stock hits 52-week low at 4.08 USD - Investing.com
BTIG Research Lowers Ardelyx (NASDAQ:ARDX) Price Target to $14.00 - MarketBeat
Ardelyx (NASDAQ:ARDX) Hits New 1-Year Low After Earnings Miss - MarketBeat
Ardelyx, Inc. (ARDX) Investor Outlook: Analyzing the 220% Potential Upside in Biotechnology - directorstalkinterviews.com
ARDX Looks 53.5% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Is Ardelyx Inc (ARDX) Undervalued After Q2 Earnings Miss? EPS of - GuruFocus
ARDX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Ardelyx Inc (ARDX) (Q2 2026) Earnings Call Highlights: Record Revenue of $118M Driven by Strong ... - Yahoo Finance
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
Ardelyx (NASDAQ:ARDX) Announces Quarterly Earnings Results - MarketBeat
Ardelyx Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Ardelyx cuts guidance as stock sinks in Q2 2026 - Investing.com
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):